Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

• Status: Not yet recruiting
• Trial end date: 2023-04-28
• Target enrollment: 0
• Participant gender: Female

Summary

This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response following daily oral dosing for 5 days of GSK3882347 in an adult female with uncomplicated urinary tract infections (uUTI). Comparator nitrofurantoin will be included in the study to ensure unbiased reporting of safety events. The study will be separated into 2 cohorts. Cohort 1 consists of an inpatient treatment period and PK analysis at frequent timepoints. Cohort 2 includes an outpatient treatment period and PK analysis conducted less frequently, at key trough timepoints.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Nitrofurantoin

Criteria

Inclusion Criteria:

• Participants must be greater than or equal to (>=)18 years of age and less than or equal to (<=)70 years.

• The participant has 2 or more of the following clinical signs and symptoms of uncomplicated urinary tract infections (uUTI) with onset less than or equal to (<=) 72 hours of the screening assessment: dysuria, frequency, urgency, or lower abdominal pain.

• Participant has nitrite and pyuria from a pretreatment clean-catch midstream urine sample

• Participants with body mass index (BMI) greater than or equal to (>=) 19.0 kilograms per square meter (kg/m^2).

• A female participant is eligible to participate who is not pregnant (as confirmed by a highly sensitive pregnancy test before the first dose of study intervention) or breastfeeding and one of the following conditions apply:

1. Woman participant of non-childbearing potential (WONCBP) Or

2. Woman participant of childbearing potential (WOCBP) using a contraceptive method that is highly effective, with a failure rate of less than (<) 1 percentage (%), during the study intervention period

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.

Exclusion Criteria:

• The participant has a BMI greater to or equal (>=) 40.0 kg/ m^2 or a BMI >=35.0 kg/ m^2 with obesity related health conditions such as high blood pressure or uncontrolled diabetes (non-fasting glucose value >300 milligram/deciliter [mg/dL]).

• The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications.

• The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis.

• The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction of the urinary tract, primary renal disease, or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract.

• The participant has an indwelling catheter, nephrostomy, ureteral stent, or other foreign material in the urinary tract.

• The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptoms onset >=96 hours before the screening assessment, or a temperature >=101 degree Fahrenheit (°F) (>=38 degree Celsius [°C]), flank pain, chills, or any other manifestations suggestive of upper UTI.

• The participant has anuria, oliguria, or significant impairment of renal function.

• The participant presents at enrollment with a suspected sexually transmitted infection.

• A positive confirmation of Coronavirus Disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-19.

• The participant has received treatment with other systemic antimicrobials or systemic antifungals within 4 weeks before study entry.

• Regular alcohol consumption within 6 months prior to the study with an average weekly intake of >14 units for females and one unit is equivalent to approximately 8 g of alcohol: a half-pint (250 ml) of beer, one glass (125 mL) of wine or one (35 mL) measure of spirits.

• Unable to take nitrofurantoin. E.g. hypersensitivity to the active substance.